Dyslipidaemia is a well-known dose-dependent adverse effect of mTOR inhibitors that is thought to occur through down-regulation of low-density lipoprotein receptors and inhibition of lipoprotein lipase activity [16]. The gene discussed is LDLR; the disease is inherited lipid metabolism disorder.